(NASDAQ: NCNA) Nucana's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 71.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 105.36%.
Nucana's earnings in 2025 is -$36,211,842.On average, 6 Wall Street analysts forecast NCNA's earnings for 2025 to be -$154,792,025,432, with the lowest NCNA earnings forecast at -$265,117,552,700, and the highest NCNA earnings forecast at -$34,635,922,662. On average, 6 Wall Street analysts forecast NCNA's earnings for 2026 to be -$25,356,808,318, with the lowest NCNA earnings forecast at -$24,362,097,249, and the highest NCNA earnings forecast at -$26,101,801,127.
In 2027, NCNA is forecast to generate -$54,099,380,044 in earnings, with the lowest earnings forecast at -$85,896,838,484 and the highest earnings forecast at -$19,349,003,179.